Centogene N V's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Centogene N V (CNTG) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Centogene N V vs Its Competitors
- TTM: Trailing 12-month revenue of 54M vs 21,088M combined for tracked competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs decelerating (-24.1%) for its tracked peer group.
- Growth: Centogene N V generated 2.2% revenue growth year over year in Q4 2023, vs 6.0% for its tracked competitors combined.
- Profitability: Its -73.3% net margin compares with -14.9% for the peer group.
- Peer revenue share: Centogene N V accounted for 1.3% of combined revenue among its tracked peer group, down from 1.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.14M compares with $0.27M for the peer group (0.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CNTG Sales vs. its Competitors, Q4 2023
Centogene N V reported revenue growth of 2.16 % year on year in Q4 2023, below its competitors' combined revenue growth of 5.98 %.
With a net margin of -73.26 %, Centogene N V reported lower profitability than its competitors (-14.91 %).
Centogene N V generated 1.34 % of the combined sales of its peer group, down from 1.39 % a year earlier.
Centogene N V vs. its Competitors, Q4 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Centogene N V and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Centogene N v | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Centogene N V's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 5.7% year over year, combined, vs 2.2% for Centogene N V. Centogene N V's share of combined industry revenue moved from 0.10% to 0.09%, a gain of 0.00 percentage points.
Centogene N V's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Centogene N v | - | - | - | - |
| Competitors combined (16) | ||||
| High-Confidence Competitors (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CNTG Stock Performance relative to its Competitors
CNTG Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Caredx Inc | 282.9% | Outperformed |
| 2 | Guardant Health Inc | 282.9% | Outperformed |
| 3 | Personalis Inc | 282.9% | Outperformed |
| 4 | Natera Inc | 282.9% | Outperformed |
| 5 | Exact Sciences Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Centogene N V's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Centogene N V's Comment on Competition and Industry Peers
Publicly Traded Peers of Centogene N v
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Centogene N v | 9.01 | 54.32 |
| Natera Inc | 58,997.99 | 2,707.08 |
| Quest Diagnostics Inc | 26,613.44 | 11,560.00 |
| Guardant Health Inc | 23,561.31 | 1,183.11 |
| Exact Sciences Corporation | 19,599.02 | 3,245.31 |
| Veracyte Inc | 3,711.55 | 544.74 |
| SUBTOTAL | 138,831.53 | 21,616.21 |
Sign in to see all competitors of Centogene N v .
Sources: Centogene N v's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Centogene N v versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Centogene N V's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Takeda | Named by the company | 85% |
| Genedx Holdings Corp | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Centogene N V's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Centogene N V's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Natera Inc | Reportable 100.00 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 97.86 % |
| Guardant Health Inc | Reportable 100.00 % |
| Veracyte Inc | Reportable 100.00 % |
| Caredx Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Centogene N V's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Centogene N v | 9 | 135,797 | -99,490 |
| Natera Inc | 58,998 | 440,892 | -31,327 |
| Quest Diagnostics Inc | 26,613 | 202,807 | 19,526 |
| Guardant Health Inc | 23,561 | 472,109 | -180,940 |
| Exact Sciences Corporation | 19,599 | 450,738 | -28,882 |
| Veracyte Inc | 3,712 | 721,503 | 151,633 |
| PEERS TOTAL | 138,823 | 268,681 | -17,468 |
Centogene N V's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Natera Inc | United States 98.24 % |
| Guardant Health Inc | United States 94.35 % |
| Exact Sciences Corporation | United States 93.11 % |
| Caredx Inc | United States 96.56 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Centogene N V's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-24.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Centogene N V's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Centogene N v | 0.44 | 1.02 | - |
| Natera Inc | - | 3.14 | 0.05 |
| Quest Diagnostics Inc | 0.22 | 1.22 | 0.76 |
| Guardant Health Inc | 2.56 | 4.29 | - |
| Exact Sciences Corporation | 1.22 | 2.68 | 0.95 |
| Veracyte Inc | 4.95 | 8.11 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Centogene N V's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Centogene N v | Q4 2023 | +2.2 % | - |
| Natera Inc | Q2 2026 | +37.7 % | - |
| Quest Diagnostics Inc | Q2 2026 | +10.2 % | +12.8 % |
| Guardant Health Inc | Q2 2026 | +44.3 % | - |
| Exact Sciences Corporation | Q4 2025 | +23.1 % | - |
| Veracyte Inc | Q2 2026 | +23.4 % | - |
| PEERS TOTAL | +16.0 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Centogene N V's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Centogene N v | Q4 2023 | +12.8 % | -89.1 % |
| Natera Inc | Q2 2026 | -99.3 % | +144.9 % |
| Quest Diagnostics Inc | Q2 2026 | +10.9 % | +27.8 % |
| Guardant Health Inc | Q2 2026 | +42.8 % | +108.2 % |
| Exact Sciences Corporation | Q4 2025 | +19.5 % | - |
| Veracyte Inc | Q2 2026 | -91.4 % | +122.3 % |
Centogene N V's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Centogene N v | - | - | - |
| Natera Inc | - | - | - |
| Quest Diagnostics Inc | 6.74% | 8.05% | 14.85% |
| Guardant Health Inc | - | - | - |
| Exact Sciences Corporation | - | - | - |
| Veracyte Inc | 8.04% | 8.15% | 8.64% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Centogene N V's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Centogene N v | - | 0.17 |
| Natera Inc | - | 21.79 |
| Quest Diagnostics Inc | 25.17 | 2.30 |
| Guardant Health Inc | - | 19.91 |
| Exact Sciences Corporation | - | 6.04 |
| Veracyte Inc | 32.08 | 6.81 |
| PEERS AVERAGE | - | 6.42 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.